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Introduction: Phosphatase and tensin homolog (PTEN) loss
is frequently observed in NSCLC and associated with both
phosphoinositide 3-kinase activation and tumoral immu-
nosuppression. PTEN immunohistochemistry is a valuable
readout, but lacks standardized staining protocol and cutoff
value.
Methods: After an external quality assessment using SP218,
138G6 and 6H2.1 anti-PTEN antibodies, scored on webbook
and tissue microarray, the European Thoracic Oncology
Platform cohort samples (n ¼ 2245 NSCLC patients, 8980
tissue microarray cores) were stained with SP218. All cores
were H-scored by pathologists and by computerized pixel-
based intensity measurements calibrated by pathologists.
Results: All three antibodies differentiated six PTENþ
versus six PTEN- cases on external quality assessment. For
138G6 and SP218, high sensitivity and speciﬁcity was found
for all H-score threshold values including prospectively
deﬁned 0, calculated 8 (pathologists), and calculated 5
(computer). High concordance among pathologists in
setting computer-based intensities and between patholo-
gists and computer in H-scoring was observed. Because of
over-integration of the human eye, pixel-based computer
H-scores were overall 54% lower. For all cutoff values,
PTEN- was associated with smoking history, squamous cell
histology, and higher tumor stage (p < 0.001). In adeno-
carcinomas, PTEN- was associated with poor survival.
Conclusion: Calibration of immunoreactivity intensities by
pathologists following computerized H-score measurements
has the potential to improve reproducibility and homoge-
neity of biomarker detection regarding epitope validation in
multicenter studies.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: PTEN; NSCLC; External quality assessment;
Computer-based intensity measurement;
Immunohistochemistry
Introduction
Phosphatase and tensin homolog (PTEN) is a major
tumor suppressor with pleiotropic functions on cell
survival, proliferation, and chromosomal integrity.1,2
Cytosolic loss of function (PTEN-) leads tohyperactivation of the phosphoinositide 3-kinase
(PI3K)/AKT/mammalian target of rapamycin signaling
pathway, an event which is common to NSCLC.3,4 Loss of
nuclear PTEN leads to an unstable genome with
increased mutational burden, sensitizing cells to
DNA-targeting drugs such as cisplatin.5,6 There is no
validated clinically effective special treatment for PTEN-
cancers yet, but substantial research and drug develop-
ment for the PTEN/PI3K axis is ongoing, in particular
regarding PI3K inhibitors, for which PTEN- is a surrogate
marker. There are phase I and II clinical trials with PI3K
inhibitors in solid tumors and NSCLC, respectively, as
well as in castration-resistant prostate carcinoma
requiring assessment of PTEN status.7-9
PTEN is not only an important predictive biomarker
for PI3K inhibition, but it has recently been reported that
PTEN- might be a mechanism of resistance to cancer
immunotherapy, for example, in metastatic uterine
leiomyosarcoma.10 In mouse melanoma cells, PTEN-
promoted resistance to T cell–mediated immunotherapy
such as anti–programmed death 1/programmed death
ligand 1 (PD-L1), by decreasing T cell inﬁltration and
expansion in tumors.11 Such loss causes an immune-
suppressive microenvironment by activation of regula-
tory T cells and inhibition of natural killer cells.12,13 In
lung squamous cell carcinomas (LSCC) loss of liver kinase
B1 (LKB1) and PTEN led to elevated PD-L1 expression.14
However, in high-grade lung neuroendocrine carcinoma,
no signiﬁcant correlation among PTEN loss, immune cell
inﬁltration, and PD-L1 expression on either tumor cells or
immune cells was found.15 Finally, there are different
micro-RNAs (miR-21, miR-92b, R-26b, and miR-181a)
regulating PTEN expression, thereby affecting cell
growth, migration, and resistance/sensitivity to
platinum-based chemotherapies.16
The poor prognostic value of PTEN- has been
described in various cancers.17-19 In NSCLC, two studies
in 2012 showed that protein loss as measured by
immunohistochemistry (IHC) occurs in up to 21% or up
to 59% of LSCC. For lung adenocarcinomas (LADC), the
frequencies were 4% and 34%, respectively.20,21 Both
studies used the 138G6 antibody and PTEN- was deﬁned
as absence of any immunoreactivity. An earlier study in
2005 found a complete loss or reduced PTEN protein
expression in 74% of NSCLC, whereby reduced expres-
sion was deﬁned as positive staining of any intensity in
less than 50% of the tumor cells using the 6H2.1 anti-
body.22 In high-grade lung neuroendocrine carcinoma,
December 2018 Computer-Based Intensity Measurement 1853complete loss of PTEN protein was found in 9.5% using
the 28H6 antibody.15
Therefore, clinical assessment of PTEN status is
important, but lacks standards. Determination of protein
loss by IHC is considered the best approach, as it in-
tegrates various regulatory networks acting on the
enzyme. IHC is assumed to be superior to sequencing
because more PTEN- cases have been detected by IHC
than by sequencing in endometrial carcinoma.23 In
particular, PTEN protein loss was detected by IHC in 44%
of cases classiﬁed as PTEN wild-type by sequencing. In
high-grade lung neuroendocrine carcinomas, PTEN IHC
expression had no correlation with PTEN mutation status
assessed by genomic analysis.15 Given that PTEN is a
tumor suppressor, protein loss rather than over-
expression is pathologically and clinically relevant.
Therefore, the low-level expression range close to
H-score 0 is crucial to evaluate a potential PTEN-.
Mindful of the discrepant results for the 138G6
antibody, we ﬁrst evaluated different staining protocols
for PTEN IHC across the European Thoracic Oncology
Platform (ETOP) laboratories and determined an optimal
H-score threshold value for PTEN-. The SP218 clone was
used alongside the established 138G6 and 6H2.1 anti-
bodies. Pathologists’ H-scores were compared with a
novel approach of objective computerized pixel-based
intensity measurement calibrated by pathologists. We
investigated the prevalence of PTEN- and its correlation
with clinicopathologic data in the ETOP Lungscape
cohort of 2245 resected NSCLC patients.Material and Methods
External Quality Assessment of PTEN IHC
An external quality assessment (EQA) was performed
using three different anti-PTEN antibodies (rabbit
monoclonal SP218 antibody [Spring Bioscience, Cat. No.
M5180], rabbit monoclonal 138G6 antibody [Cell
Signaling Technologies, Cat No. 9559], and mouse
monoclonal 6H2.1 antibody [DAKO, Cat. No. M3627]) on
two automated IHC platforms (Ventana Benchmark and
Leica Bond-Max). To avoid differences in preanalytical
conditions, all ETOP labs used the Ventana Ultra auto-
mated platform with standardized reagents, in partic-
ular, the same batch of SP218 antibody was distributed
to all ETOP centers (Supplementary Table 1).
Overall, 12 cases were retrieved from our archive
according to the PTEN IHC result indicated in the sign-
out report using the 6H2.1 antibody. These 12 cases
included ﬁve positive and ﬁve negative surgical speci-
mens, respectively, and two cell lines, PTEN- PC3 and
PTENþ H460.24 Firstly, whole sections were centrally
stained and digitized on a webbook (Institute of
Pathology Zurich) using all three antibodies. Secondly,these cases were assembled in tissue microarrays
(TMAs) and stained locally (each ETOP laboratory).
Locally stained TMA sections were sent back to Zurich
for computer analysis. To compare SP218 data with the
136G6 antibody, we performed IHC on the Zurich ETOP
TMAs (n ¼ 305 patients) with the latter antibody.
First, a visual presentation was given to train
pathologists, including low-expression cases of H-scores
of 50 or less. IHC results were discussed at a follow-up
meeting. Second, PTEN staining and H-scoring in-
structions were distributed. Pathologists received
all EQA results from their colleagues and associated
statistics. Scoring results were examined by U.R. and A.S.
and discussed with pathologists. Third, permission for
further staining and scoring of the entire ETOP cohort
with the SP218 antibody was delivered.
ETOP NSCLC Patient Lungscape Cohort and
Website Databases
The iBiobank has annotated comprehensive data
from 16 ETOP sites on surgically resected 2245 patients
with stage I to III NSCLC with at least 3 years of follow-
up (median follow-up, 4.8 years) full clinical history.25,26
The iBiobank also contains data on EGFR, BRAF, KRAS,
PIK3CA alterations, and ALK receptor tyrosine kinase
and MET receptor tyrosine kinase IHC. Research was
conducted according to each participating country’s
ethics and regulatory requirements for use of patient
material in research. We additionally performed in silico
PTEN mRNA expression analysis from the Kaplan-Meier
Plotter database (www.kmplot.com), consisting of 1145
lung cancer cases, including 673 LADCs and 271
LSCCs.27
PTEN Fluorescent In Situ Hybridization
EQA TMA sections of 4-mm thickness were incubated
with a dual color probe for cytoband 10q23 and region
10p11.1-q11.1 (LSI PTEN Spectrum-Orange and
CEP10 Spectrum-Green, Vysis/Abbott Molecular, Baar,
Switzerland). For each case, 100 nonoverlapping
nuclei were evaluated on a Zeiss Axioskop (Oberkochen,
Germany). Z-stacks of 20 images with 0.5-mm step
distance were merged.
H-scoring of PTEN IHC by Pathologists and
Computer
ETOP Lungscape pathologists determined H-scores
on webbook and TMA sections. The semiquantitative
score was obtained by the summation of the product of
total cellular PTEN immunoreactivity intensity (0, 1, 2,
or 3) with corresponding percentage of stained tumor
epithelia (H-score range, 0–300). Robust PTEN expres-
sion (score 2 or 3) in cancer-associated ﬁbroblasts
1854 Rulle et al Journal of Thoracic Oncology Vol. 13 No. 12(CAFs), endothelial cells, and alveolar pneumocytes
served as internal control.
Stained sections were digitalized using a Nano-
Zoomer Digital Pathology scanner (Hamamatsu, Japan)
at the maximum in-built magniﬁcation of 400. Image
analysis was performed at 200 magniﬁcation on the
virtual microscope software Leica SlidePath. Tagged
image ﬁle format pictures of tumor epithelia only were
analyzed using Image-J2 software.28 Pixel-based mea-
surement of immunoreactivity was performed using the
Lab* color space (lightness [L] and two color channels [a,
b]). White areas lacking tissue were removed in the
brightness channel, whereas blue counterstaining areas
were removed from chrominance-a and -b. The resulting
brown signal was thereafter located between red and
yellow. The threshold between the background brown
signal and speciﬁc immunoreactivity intensity score 1
was averaged from 110 representative image frames laid
on faintly stained glass (10 frames), unstained tissue
areas of a microﬂuidic tissue processor-based IHC (50
frames), and stainings without primary antibody (50
frames).29 This background setting was maintained for
all further analyses. Subsequently, three Zurich pathol-
ogists and 10 ETOP pathologists set their individual
thresholds of brown intensity scores 3, 2, and 1 for the
SP218 antibody (Supplementary Video). The 138G6
antibody stainings were scored by two other Zurich
investigators.
Computer H-scores were calculated in the same way
by multiplying percentage of positive pixel area with
respective intensity. For the one EQA whole section and
the four EQA TMA cores of each of the 12 cases, 50
frames in total were put on tumor epithelia in a semi-
automated manner. For the 97 TMAs of the 2245 patient
ETOP cohort (n ¼ 8980 cores), 4 frames per case were
used, covering largest possible areas of only vital tumor
but not CAFs or necrosis. For the computerized analysis
of the full cohort, the Zurich settings were applied on all
images from externally stained TMAs to provide uni-
formity. The frame sizes were in the range of 100–500 
100–500 pixels (1 mm ¼ 2.17 pixels), generally being
larger in the ETOP cohort than in the EQA whole sections
or the EQA TMA cores (Supplementary Fig. 1).Statistical Analysis
In the EQA dataset, the Wilcoxon nonparametric test
checked for signiﬁcant differences between PTENþ
versus PTEN- cases. Sensitivity and speciﬁcity of H-score
thresholds were calculated through receiver operating
characteristic (ROC) curves. In the ETOP cohort, the
prevalence of PTEN- and conﬁdence interval (95% CI)
was compared between patients with different clinico-
pathologic characteristics using the Fisher’s exact andthe Mantel-Haenszel tests. Associations between PTEN-
and predictive markers were evaluated by two-way
tables and the Cochran-Mantel-Haenszel test, stratiﬁed
by histology.
Clinical outcome included overall survival (OS, time
from surgery to death from any cause), relapse-free
survival (RFS, time from surgery to ﬁrst relapse or
death from any cause), and time-to-relapse (TTR, time
from surgery to ﬁrst relapse).25,26 The effect of PTEN- on
outcome was explored through Cox regression models,
adjusted for a series of patient, tumor, and surgical
characteristics and for mutations. Final models with
signiﬁcant outcome prognostic factors were based on
the backwards elimination method (Wald’s p  0.10).
Hazard ratios (HRs) and Kaplan-Meier curves were used
to illustrate observed differences in hazard.
In all exploratory analyses, results with two-sided
p  0.05 were considered signiﬁcant. Analyses were
performed using SAS version 9.4 (SAS Institute, Cary,
North Carolina) and R version 3.3.2 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
PTEN IHC
Routine diagnostic protocol was used for 6H2.1
antibody, but for the SP218 and 138G6 anti-PTEN clones,
we implemented novel protocols. To avoid differences in
preanalytical conditions, all labs used the Ventana Ultra
automated platform with standardized reagents and the
same batch of SP218 antibody (Supplementary Table 1).
Figures 1A and 1B show the performance of the three
antibodies in a PTEN- mucinous endometrial carcinoma
and representative images for different H-scores. The
methodology of computerized intensity measurement
calibrated by pathologists is presented in Figure 2. Ex-
amples of EQA TMA staining quality among centers are
presented in Supplementary Figure 2 for two cases.
EQA
Table 1 summarizes IHC and ﬂuorescence in situ
hybridization (FISH) data from the 12-case TMA and
whole sections webbook used for EQA. The webbook
analysis yielded similar results for SP218 and 138G6
antibodies. 6H2.1 stained stronger than SP218 and
138G6 (Supplementary Table 2), as in Figure 1A for a
single case (computer H-score 3 versus 0) and Figure 3A.
All antibodies could separate PTEN- from PTENþ cases
based on H-score average. All negative cases also showed
a genomic PTEN loss, ranging from 0.90 down to 0.02
CEP10/PTEN ratios. Correlation of H-scores among the
antibodies was highly signiﬁcant (p values 0.002–0.003)
with coefﬁcients 0.78 (138G6/6H2.1), 0.78 (SP218/
138G6) and 0.80 (SP218/6H2.1) (data not shown).
Figure 1. Phosphatase and tensin homolog (PTEN) immunohistochemistry. (A) Comparison of the three antibodies using a
PTEN- mucinous endometrium carcinoma from external quality assessment (EQA). Cancer-associated ﬁbroblasts (CAFs) are
stained positive and serve as internal control. (B) Representative H-scores for SP218 antibody indicated by pathologists.
Genomic PTEN loss (CEP10/PTEN ratio 0.02) is shown by ﬂuorescence in situ hybridization at 1000 magniﬁcation in lung
squamous cell carcinoma (LSCC) from EQA; CEP10 (green), PTEN (orange), and nuclei (blue). Small peripheral lymphocytes
show both CEP10 (green) and PTEN (orange) signals, but tumor nuclei only CEP10. Upper (x-axis) and right (y-axis) border
indicate distribution of ﬂuorescent intensity across merged z-stack of 20 images. HE, hematoxylin and eosin stain.
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the EQA TMA data was more balanced for intermediate
than high H-scores (ROC curves in Fig. 3B). Analyses of
these ROC curves showed that the optimal cutoff
threshold of PTEN- is mean H-score less than 5 for
computer and less than 8 for pathologists (values shown
in Fig. 3B). To address intratumoral heterogeneity, we
calculated the variation coefﬁcient among the H-scores
of the 50 randomly selected frames of the PTENþ
webbook whole sections. A value of 0.38 was obtained
for the SP218 antibody indicating little variation.
ETOP NSCLC Lungscape Cohort
Because the two antibodies SP218 and 138G6 had
similar performance in the EQA TMA, investigation was
performed to assess if they are also comparable in a bigger
sample size. Therefore, the Zurich part of Lungscape
(n ¼ 305) was investigated by both SP218 and 138G6.
Results of both pathologists’ and computer scoringsshowed a strong correlation between these antibodies
(Spearman correlation coefﬁcient between the two anti-
bodies: 0.73 for computer scores and 0.93 for patholo-
gist’s scores; p < 0.001 in both cases). SP218 was chosen
for further analysis of the full ETOP Lungscape cohort.
In this cohort with available PTEN information, the
median patient age is 66.4 years, 66% are males, and
34% females. In this group, 53.9% of patients are
former-, 31.5% current-, and 10.6% nonsmokers. Stage
distribution is as follows: IA 22.4%, IB 25.9%, IIA 16.8%,
IIB 12.2%, IIIA 20.8%, and IIIB 1.9%. In this group,
48.7% of tumors are LADC, 43.8% LSCC, 4.4% large cell
carcinoma, and 3.2% other histology. Median tumor size
is 3.5 cm. Available 5-year OS is 53.6% (95% CI:51.3%–
55.9%), 5-year RFS is 46.5% (95% CI: 44.3%–48.8%),
and 5-year TTR is 56.7% (95% CI: 54.4%–59.0%).
Correlations of PTEN immunoreactivity with clinico-
pathologic parameters are summarized in Table 2.
PTEN-, using deﬁned cutoffs for SP218, was detected in
Figure 2. Methodology of computerized analysis of phosphatase and tensin homolog (PTEN) immunoreactivity based on
pathologists’ calibrated pixel intensity measurement. In FIJI Lab color space, color threshold was adjusted, performing three-
fold background normalization and followed by averaged intensity calibration by pathologists. The threshold between brown
signal intensity 1 and blue-grey color of hematoxylin/bluing reagent counterstaining with eventual faint brownish tone
(intensity score 0) was averaged from 110 representative image frames laid on faintly stained glass, unstained tissue areas of
a microﬂuidic tissue processor-based immunohistochemistry, and stainings without primary antibody. Thresholds for intensity
2 or 3 levels were averaged from 3 Zurich pathologists and used for H-score calculation. Note: For subsequent analysis of both
external quality assessment and European Thoracic Oncology Platform (ETOP) cohort frames of size 100-500  100-500 pixels
were laid on tumor epithelia only.
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cutoff ¼ 8) or 1304 of 2208 (59.1%, based on the
computer cutoff ¼ 5). In addition, when the H-score
0 cutoff was tested for the pathologists, 981 of 2245
patients (43.7%) were PTEN-. For all three thresholds,
PTEN- correlated with former and current smokers,
LSCC histology, higher stage, and larger tumor size.
According to pathologists’ scores, PTEN- was morecommon to patients who obtained adjuvant chemo-
therapy as well as radiotherapy. Correlation with other
biomarkers is presented in Supplementary Table 3. In
brief, PTEN- correlated with ALK receptor tyrosine ki-
nase and MET receptor tyrosine kinase.
Overall (n ¼ 2245), the median OS was 67.9 months
(95% CI: 62.0–74.3 months), the median RFS was 50.8
months (95% CI: 45.8–56.4 months), and the median
Table 1. External Quality Assessment Results
Diagnosis
Mean H-score
FISHEQA TMA (Local) EQA Webbook (Central)
SP218 SP218 138G6 6H2.1
CEP10/PTENPathologists Computer Pathologists Computer Pathologists Computer Pathologists Computer
Endometrioid endometrium carcinoma
PTEN- 17 4 13 1 4 0 23 59 0.56
Mucinous endometrium carcinoma
PTEN- 1 1 0 0 0 0 4 2 0.90
Lung adenocarcinoma
PTENþ 97 53 96 23 103 28 277 187 0.99
PTEN- 1 0 1 0 1 0 17 5 0.60
PTEN- 1 1 7 0 1 0 53 63 0.58
Lung squamous cell carcinoma
PTENþ 190 77 209 130 178 62 245 121 1.09
PTEN- 0 0 1 0 7 0 18 6 0.02
Glioblastoma
PTENþ 148 65 232 111 198 61 296 200 1.07
Prostate carcinoma
PTENþ 91 58 127 76 82 22 186 129 1.00
Solid carcinoma fallopian tube
PTENþ 68 30 149 73 98 10 248 123 1.11
Lung carcinoma cell line h460
PTENþ 133 54 131 36 228 123 265 143 1.04
Prostate carcinoma cell line PC3
PTEN- 17 8 0 0 0 0 25 1 0.59
Note: Summary of PTEN IHC H-scores averaged across ETOP centers for the 12 EQA cases ordered by histology. These cases were stained with SP218, 138G6 and
6H2.1 for central webbook and SP218 only for local TMA. All cases were stained with a PTEN FISH probe. EQA TMA (both computer and pathologists) and EQA
webbook (pathologists, all three antibodies) data are based on 16 evaluations/scorings per case, whereas EQA webbook data evaluated by computer are based
on 50 pictures per case for each antibody. FISH analysis was performed by analyzing 100 cells for each case. EQA, external quality assessment; TMA, tissue
microarray; FISH, ﬂuorescence in situ hybridization; PTEN, phosphatase and tensin homolog; IHC, immunohistochemistry; ETOP, European Thoracic Oncology
Platform.
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For LADC, PTEN- (based on the pathologists’ scores
cutoff ¼ 0) was a negative prognostic factor for all
endpoints: OS (p ¼ 0.004), RFS (p ¼ 0.002), and TTR
(p ¼ 0.003) (data not shown). This negative effect of
PTEN- is further shown when dividing the H-score av-
erages in four levels (5, >5 to 20, >20 to <100, and
100) (Supplementary Figs. 3A and B; p < 0.05 for both
pathologists and computer). In the adjusted Cox model
depicted in the forest plot (Supplementary Fig. 4A),
the HR for PTEN- versus PTENþ was 1.21 (95% CI:
1.01–1.46; p ¼ 0.04) for the LADC and the pathologist
threshold 0, indicating higher death risk by 21%. Similar
results were obtained for pathologists’ threshold 8,
computer threshold 5 (Supplementary Figs. 4B and C).
Finally, the Kaplan Meier-plotter database of 1145
independent NSCLC patients was interrogated for PTEN
mRNA expression dichotomized at the median. PTEN
expression in all NSCLC correlated with better OS (HR:
0.49, p < 0.001), matching our results (Supplementary
Fig. 5). Regarding histologic subtype, high PTENexpression in LADC, but not LSCC, was also associated
with better OS (HR: 0.41, p < 0.001).
Comparison of Pathologists Versus Computer
Scoring
The intraclass correlation coefﬁcient (ICC) was
calculated to evaluate the resemblances of H-scores of
common cases among different centers participating in
the EQA. The ICC of the EQA TMA PTEN stainings for
pathologists was 0.72, whereas that for the computer
was 0.66. The ICC of the EQA webbook for pathologists is
0.88 using the SP218 antibody.
Moreover, the EQA TMA analysis showed a lower
intercenter variability for computer-derived H-scores
compared to the pathologists. The difference in calibra-
tion threshold settings between three internal Zurich
pathologists and 10 ETOP pathologists was minimal
(Fig. 4A). Furthermore, the computer H-scores were on
average 54% lower than the pathologists were (Fig. 4B).
Regarding the ETOP cohort analysis, signiﬁcant
correlations were found for pathologists versus
Figure 3. Setting optimal threshold in external quality assessment. (A) Boxplots of H-scores for external quality assessment
(EQA) webbook phosphatase and tensin homolog (PTEN-) and PTENþ cases for the three antibodies scored by pathologists and
computer. These results indicates that 6H2.1 antibody stains stronger. (B) Receiver operating characteristic curves with
optimal thresholds for PTEN- calculated from EQA (pathologists H-score value ¼ 8, computer H-score value¼ 5) together with
corresponding speciﬁcity/sensitivity (0.92/0.94) and (0.95/0.92) for predicting PTEN-. AUC, area under the curve.
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of the four cores (all coefﬁcients >0.55; p < 0.001)
(data not shown). Further analyses used the four-core
average. The frequency distributions of pathologists
and computer scores are shown in Figure 4C using
ﬁve H-score categories: (1) 0, (2) >0 to 5, (3) >5 to
20, (4) >20 to <100, and (5) 100. As in the EQA
TMA analysis, the computerized methodology gener-
ally produced lower H-score values with the exception
of H-scores close to 0. In the range close to 0,pathologists mostly scored exactly 0, whereas the
computer mostly gave values of 5 or less. The oppo-
site phenomenon was observed in the high-expression
range, where the pathologists scored higher than the
computer.Discussion
In this study, different IHC protocols were investi-
gated in the multicenter ETOP Lungscape cohort to
Table 2. Correlations of PTEN Immunoreactivity Using the SP218 antibody With Clinicopathologic Parameters of Lungscape
Cohort Patients
Characteristics
Pathologists Computer
Threshold: 0 Threshold: 8 Threshold: 5
n ¼ 2245
PTEN-
n ¼ 981
(43.7%) p Value
PTEN-
n ¼ 1097
(48.9%) p Value n ¼ 2208
PTEN-
n ¼ 1304
(59.1%) p Value
Age at surgery, y, n (%)
<60 634 274 (43.2) 0.91 313 (49.4) 0.90 622 377 (60.6) 0.65
60-70 804 350 (43.5) 388 (48.3) 794 466 (58.7)
>70 806 357 (44.3) 396 (49.1) 791 461 (58.3)
Gender, n (%)
Male 1479 698 (47.2) <0.001 770 (52.1) <0.001 1450 866 (59.7) 0.39
Female 766 283 (36.9) 327 (42.7) 758 438 (57.8)
Smoking history, n (%)
Former 1210 554 (45.8) <0.001 615 (50.8) <0.001 1191 702 (58.9) <0.001
Current 707 337 (47.7) 374 (52.9) 696 438 (62.9)
Never 237 58 (24.5) 72 (30.4) 230 106 (46.1)
Adjuvant CT, n (%)
Yes 495 258 (52.1) <0.001 288 (58.2) <0.001 486 311 (64.0) 0.014
No 1457 620 (42.6) 694 (47.6) 1431 824 (57.6)
Adjuvant RT, n (%)
Yes 111 67 (60.4) <0.001 77 (69.4) <0.001 110 72 (65.5) 0.16
No 1827 798 (43.7) 890 (48.7) 1793 1047 (58.4)
Histology, n (%)
Adenocarcinoma 1093 409 (37.4) <0.001 456 (41.7) <0.001 1073 581 (54.1) <0.001
Squamous cell 983 503 (51.2) <0.001a 563 (57.3) <0.001a 970 628 (64.7) <0.001a
Large cell 98 46 (46.9) <0.001b 48 (49.0) <0.001b 95 60 (63.2) <0.001b
Other 71 23 (32.4) 30 (42.3) 70 35 (50.0)
Stage, n (%)
I 1083 438 (40.4) 0.002c 495 (45.7) 0.0021c 1068 588 (40.4) <0.001
II 653 297 (45.5) 329 (50.4) 640 391 (45.4) <0.001c
III 509 246 (48.3) 273 (53.6) 500 325 (65.0)
Tumor size, n (%)
4 cm 1394 541 (38.8) <0.001 610 (43.8) <0.001 1371 748 (54.6) <0.001
>4 cm 849 439 (51.7) 485 (57.1) 835 556 (66.6)
Note: Fischer’s exact statistical test is used, unless indicated otherwise.
aCategories “large cell” and “other” excluded.
bCategories “large cell” and “other” combined.
cMantel-Haenszel test.
CT, chemotherapy; RT, radiotherapy; PTEN, phosphatase and tensin homolog.
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epithelia of formalin-ﬁxed parafﬁn-embedded tissue
blocks of resected chemotherapy-naïve NSCLC patients.
In our novel approach, pathologists calibrated the
computerized image analysis of PTEN IHC. Thereby,
pathologists’ interpretations were directly compared
with independent computer-calculated H-scores on
scanned slides obtained from pathologists’ own intensity
settings on an individual basis.
PTEN IHC and FISH
Comprehensive PTEN IHC testing originally used
three monoclonal antibodies (28H6, 10P03, and 6H2.1)
and one polyclonal on endometrial carcinoma. 6H2.1-
derived immunoreactivity correlated best with PTENgene alterations.30 Recent studies in prostate, renal cell,
breast, endometrial, and vulvar carcinomas conﬁrmed
this ﬁnding.31-34 Novel clones such as 138G6, SP218, and
D4.3 were developed and tested on genetically deﬁned
PTEN þ/- cell lines.35 SP218 and 138G6 are rabbit
monoclonal antibody (RabMAb) with high afﬁnities of
10-12 equilibrium dissociation constant (KD) in contrast to mouse
monoclonal antibody (MmAb) with 10-9 KD. In this study
the MmAb 6H2.1 although stained stronger than the two
RabMAbs. Based on EQA results, performance of 6H2.1
should rather be considered overstaining, as, for
example, lung carcinomas with genomic PTEN- showed
H-scores up to 63. The synthetic CTD peptide for SP218
and 138G6 is most likely the same, explaining the similar
H-score values in the EQA.
Figure 4. Performance of pathologists versus computer. (A) Brown tones intensity thresholds without background set by
pathologists from Zurich (red triangle) and 10 European Thoracic Oncology Platform (ETOP) centers (dots) on three image
frames of one webbook case (phosphatase and tensin homolog [PTEN]þ lung adenocarcinoma [LADC]) stained with SP218. (B)
Comparison of H-score variation between pathologists and computer for six PTEN- (left, y axis divided into 0 to 0.04 and 0 to
80 for three cases each) and six PTENþ (right) webbook cases, stained centrally in Zurich. Computer H-scores for every
center were calculated based on intensity thresholds set by the respective European Thoracic Oncology Platform (ETOP)
pathologists. Pathologists H-scores reﬂect own scoring of webbook in each ETOP center. (C) Population tree comparing
frequencies of H-score categories between pathologists and computer. H-scores of whole ETOP cohort from 97 tissue
microarrays stained with SP218 were divided in ﬁve categories (1) 0, (2) >0 to 5, (3) >5 to 20, (4) >20 to <100, and
(5) 100.
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ations with subclonal deletions. We used the CEP10/
PTEN ratio to measure the global genomic PTEN
status. Most PTEN- cases were close to hemizygous or
homozygous loss, except for the mucinous endome-
trium carcinoma with a value of 0.90. Cells are
ultrasensitive to subtle changes of PTEN dosage.
Hypermorphic mice with a 20% reduction in mRNA
PTEN levels have already developed a spectrum of
tumors.36
Computerized Analysis of Semiquantitative
Intensity Marks
In our computerized pixel-based methodology, chro-
mogenic intensity levels were calibrated by averaged
settings of surgical pathologists with more than 10 years
of IHC experience. Such thresholds may serve as “in-
tensity reference marks” to be put in the continuous
variable of brown tone intensity. Evidently, the absolute
position of the intensity marks 1, 2, or 3 on the 255 to
0 Lab scale would be dependent on the general staining
intensity of a given antibody. Here, these marks were
laid on the brown tone scale in a rather close and
comparable fashion by pathologists. It remains to be
seen if the use of the entire brown tone intensity spec-
trum as continuous variable would add further value in
comparison to the intensity mark approach. In our study,
total cellular immunoreactivity was scored. A drawback
of this approach is the lack of intracellular signal local-
ization to either cytosol or nucleus.
Computerized analysis of automated quantitative
analysis–based immunoﬂuorescence allowed for
measuring cytosolic PTEN- in NSCLC.37 More recently,
chromogenic PTEN IHC was measured in NSCLC in the
red-green-blue spectrum using Aperio ImageScope soft-
ware and 6H2.1 antibody.34,38 A similar approach was
used for scoring PTEN expression in larynx carcinoma.39
Furthermore, its intracellular localization, intensity, and
frequency was assessed using 3D Histech Panoramic
Viewer software and antibody clones 6H2.1, 138G6, and
Ab6-28H6.40
Comparison of Pathologists Versus Computer
ETOP pathologists were challenged with their own
computerized intensity settings. They were asked to
semiquantitatively set intensity thresholds on a com-
puter screen on representative images. Thereafter, they
scored the EQA webbook on screen. These scores were
compared with computerized analysis on the same im-
ages using their own intensity settings. More narrow
data was obtained by the computer.
Scoring of brown tone intensity of IHC by the hu-
man eye is assumed to be subjective. Agreement onscores 0 and 3 is usually high. Scores 1 and 2 are more
critical, but reasonable interobserver kappa values of
0.7 or higher can be achieved if visual dictionaries are
provided.33,41 The integration of various frequencies
with different intensities is particularly challenging
because the perception of immunoreactivity on tumor
epithelia by the human eye will be inﬂuenced by the
staining intensity of surrounding CAFs, a phenomenon
called Chubb illusion. Chubb illusion is an error in
visual perception in which the apparent contrast of an
object varies substantially to most viewers depending
on its relative contrast to the ﬁeld on which it is dis-
played.42 Therefore, high density of strongly PTENþ
CAFs tends to result in lower PTEN scores for the
tumor epithelia when assessed by pathologists but not
by the computer.
Regarding perception of stained area, overscoring
may occur due to the fact that strongly stained areas are
preferentially recognized in terms of percent surface.
Here lies the strength of objective pixel-based intensity
measurements leading to approximately 50% lower but
more homogenous scores. Intercenter variability was
also lower when the computer was used, which is useful
for multicenter studies. Pathologists downscaled small
H-scores of up to 5 resulting from few brown pixels
(computer), to the “0” value whereas brown intensities
greater than 20 (computer) were overrated and given
values often greater than 100.
Setting Intensity Threshold for PTEN-
Because of the absence of a consensus, different
thresholds were considered: for pathologists 0 (a priori)
and 8 (calculated), and for computer 5 (calculated).
From a cell biological point of view, it is conceivable that
alternative cutoff values beside the a priori H-score
0 could be used for correlation with clinicopathologic
parameters. It is important but also challenging to set an
optimal threshold in the lower range of H-scores.
Computerized analysis is thereby of great help to
distinguish small differences in brown tones. Admittedly,
using the different thresholds 0, 5, or 8, no major
differences in correlation between PTEN- and clinico-
pathologic parameters were found.
Correlation With Clinicopathologic Parameters
It has been shown that tumor cells are ultrasensitive
to subtle PTEN dosage alterations, and a hypermorphic
allele with a remaining 80% of wild-type activity
increased tumor formation in mice.43 Complete PTEN
loss triggered cellular senescence, which protected
against tumor initiation or progression.44 Therefore,
partial PTEN loss is advantageous for initial tumorigen-
esis, whereas complete loss promotes rapid tumor
1862 Rulle et al Journal of Thoracic Oncology Vol. 13 No. 12growth after senescence mechanisms are impaired in
advanced tumors. Our data ﬁt with this concept as larger
tumors showed a stronger PTEN loss. Our results also
conﬁrm the dismal prognostic value of PTEN- in early-
stage adenocarcinomas.45 We observed a protein loss
in 44% (pathologists, threshold 0) and 59% (computer,
threshold 5) of NSCLC, respectively. The frequencies
were 51%/65% for LSCC and 37%/54% for LADC. Our
results thus match with other NSCLC studies where
PTEN- occurred in 21% or 59% of LSCC, but 4% or 34%
in LADC, respectively.20,21 These studies used the 138G6
antibody and PTEN- was deﬁned as absence of any
immunoreactivity.
Clinical Signiﬁcance
The main goal of medical expert systems is not to
replace human experts, but rather to support them. In
digital pathology, computerized image analysis using
pixel-based measurement is of great help for many
tasks — such as measurement of immunohistochemical
brown staining across tumor surfaces. Thus, using the
computer we add value to H-scores.
Here, we present a novel approach of pathologist’s
calibrated IHC analysis of the PTEN protein. Pathologists
thereby compare their interpretations with computer-
calculated H-scores derived from their own intensity
settings. Because of unbiased integration of pixel in-
tensities in a given frame-of-interest, more homogenous
H-scores are achieved. Such algorithms may improve
reproducibility of biomarker detection regarding epitope
validation in international clinical trials that stratify
patients according to protein expression values.
Conclusion
In summary, calibration of immunoreactivity
intensities by pathologists, following computerized
H-score measurements, has the potential to improve
reproducibility and homogeneity of biomarker detection
regarding epitope validation in multicenter studies.
Such computerized measurements are able to deliver
adequate data in the low expression range and to
conﬁrm pathologists’ scorings regarding correlations
with clinicopathologic parameters, including survival.
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